IQ-AI Ltd (IQAI) - Total Assets
Based on the latest financial reports, IQ-AI Ltd (IQAI) holds total assets worth GBX929.67K GBX (≈ $113.11 USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See IQ-AI Ltd (IQAI) shareholders funds for net asset value and shareholders' equity analysis.
IQ-AI Ltd - Total Assets Trend (1990–2024)
This chart illustrates how IQ-AI Ltd's total assets have evolved over time, based on quarterly financial data.
IQ-AI Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
IQ-AI Ltd's total assets of GBX929.67K consist of 27.1% current assets and 73.0% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 5.8% |
| Accounts Receivable | GBX165.12K | 17.8% |
| Inventory | GBX0.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX604.63K | 65.0% |
| Goodwill | GBX72.64K | 7.8% |
Asset Composition Trend (1990–2024)
This chart illustrates how IQ-AI Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IQ-AI Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: IQ-AI Ltd's current assets represent 27.1% of total assets in 2024, an increase from 13.0% in 1990.
- Cash Position: Cash and equivalents constituted 5.8% of total assets in 2024, up from 0.1% in 1990.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, an increase from 0.0% in 1990.
- Asset Diversification: The largest asset category is intangible assets at 65.0% of total assets.
IQ-AI Ltd Competitors by Total Assets
Key competitors of IQ-AI Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cogstate Ltd
AU:CGS
|
Australia | AU$64.77 Million |
|
Alcidion Group Ltd
AU:ALC
|
Australia | AU$115.63 Million |
|
Pharmx Technologies Ltd
AU:PHX
|
Australia | AU$18.82 Million |
|
Singular Health Group Ltd
AU:SHG
|
Australia | AU$12.55 Million |
|
Intrasense
PA:ALINS
|
France | €7.99 Million |
|
Careteq Ltd
AU:CTQ
|
Australia | AU$4.44 Million |
|
Newtopia Inc
V:NEWU
|
Canada | CA$664.83K |
|
Pro Medicus Ltd
AU:PME
|
Australia | AU$533.91 Million |
IQ-AI Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.40 | 0.49 | 6.22 |
| Quick Ratio | 0.40 | 0.49 | 6.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX-375.69K | GBX-319.04K | GBX1.09 Million |
IQ-AI Ltd - Advanced Valuation Insights
This section examines the relationship between IQ-AI Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.87 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 29.0% |
| Total Assets | GBX929.67K |
| Market Capitalization | $24.76K USD |
Valuation Analysis
Below Book Valuation: The market values IQ-AI Ltd's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: IQ-AI Ltd's assets grew by 29.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for IQ-AI Ltd (1990–2024)
The table below shows the annual total assets of IQ-AI Ltd from 1990 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX929.67K ≈ $113.11 |
+28.99% |
| 2023-12-31 | GBX720.74K ≈ $87.69 |
-43.14% |
| 2022-12-31 | GBX1.27 Million ≈ $154.23 |
-19.95% |
| 2021-12-31 | GBX1.58 Million ≈ $192.66 |
+10.51% |
| 2020-12-31 | GBX1.43 Million ≈ $174.35 |
-23.31% |
| 2019-12-31 | GBX1.87 Million ≈ $227.34 |
+83.58% |
| 2018-12-31 | GBX1.02 Million ≈ $123.84 |
+46.87% |
| 2017-12-31 | GBX693.00K ≈ $84.32 |
+766.25% |
| 2016-12-31 | GBX80.00K ≈ $9.73 |
-75.46% |
| 2015-12-31 | GBX326.00K ≈ $39.66 |
-22.75% |
| 2014-12-31 | GBX422.00K ≈ $51.35 |
0.00% |
| 2014-12-26 | GBX422.00K ≈ $51.35 |
-86.50% |
| 2013-12-31 | GBX3.13 Million ≈ $380.47 |
-23.62% |
| 2012-12-31 | GBX4.09 Million ≈ $498.12 |
-49.80% |
| 2011-12-31 | GBX8.15 Million ≈ $992.23 |
-57.27% |
| 2010-12-31 | GBX19.09 Million ≈ $2.32K |
+5.05% |
| 2009-12-31 | GBX18.17 Million ≈ $2.21K |
+2.34% |
| 2008-12-31 | GBX17.75 Million ≈ $2.16K |
-49.97% |
| 2007-12-31 | GBX35.48 Million ≈ $4.32K |
-1.39% |
| 2006-12-31 | GBX35.98 Million ≈ $4.38K |
+45.46% |
| 2005-12-31 | GBX24.74 Million ≈ $3.01K |
+7.09% |
| 2004-12-31 | GBX23.10 Million ≈ $2.81K |
+3.55% |
| 2003-12-31 | GBX22.31 Million ≈ $2.71K |
+0.97% |
| 2002-12-31 | GBX22.09 Million ≈ $2.69K |
0.00% |
| 2001-12-31 | GBX22.09 Million ≈ $2.69K |
+1.06% |
| 2000-12-31 | GBX21.86 Million ≈ $2.66K |
-34.84% |
| 1999-12-31 | GBX33.55 Million ≈ $4.08K |
-16.03% |
| 1998-12-31 | GBX39.95 Million ≈ $4.86K |
+114.66% |
| 1997-12-31 | GBX18.61 Million ≈ $2.26K |
+21.42% |
| 1996-12-31 | GBX15.33 Million ≈ $1.87K |
+78.24% |
| 1995-12-31 | GBX8.60 Million ≈ $1.05K |
+43.21% |
| 1994-12-31 | GBX6.00 Million ≈ $730.63 |
+51.26% |
| 1993-12-31 | GBX3.97 Million ≈ $483.03 |
+8.17% |
| 1992-12-31 | GBX3.67 Million ≈ $446.53 |
+10.48% |
| 1991-12-31 | GBX3.32 Million ≈ $404.19 |
+40.47% |
| 1990-12-31 | GBX2.37 Million ≈ $287.75 |
-- |
About IQ-AI Ltd
Imaging Biometrics Ltd., through its subsidiaries, provides clinical treatments to patients in the field of medical imaging diagnostics in the United Kingdom, Switzerland, European Union, and the United States. The company develops ready-to-use software applications for the healthcare industry; and provides technology solutions in the field of kidney stone analysis and prevention, as well as offe… Read more